Clinical trials have demonstrated the effectiveness of TMS Therapy in treating patients who have not benefited from prior antidepressant medication.Clinical trials have shown that TMS Therapy may help to reduce or diminish symptoms of depression after 4 to 6 weeks of treatment.
In an independent, randomized, controlled trial funded by the National Institute of Mental Health, patients treated with NeuroStar® TMS Therapy were four times more likely to feel their depression symptoms significantly improve, compared to a control group of patients.1
When studied over the course of a year:
1 in 2 TMS patients experienced significant improvement in their depression symptoms
1 in 3 experienced complete remission from their depression symptoms.2
In a trial with physician directed standard of care, meaning TMS Therapy could be used in conjunction with antidepressants as needed, patients who had received treatment then reported their symptom levels at 3, 6, 9 and 12 months to determine the durability of their treatments. By the end of the 12-month period, 2 out of 3 patients who had either responded or completely remitted after TMS treatment remained at the symptom levels they reported at the end of the treatment phase.1
After the end of the treatment period, only 1 in 3 patients needed to come back for maintenance TMS sessions, or ‘reintroduction’ during this 12-month period.1
TMS+YOU is an online community and national patient advocacy site for TMS Therapy. Those considering Transcranial Magnetic Stimulation can connect with patients who have had the treatment to answer questions, share insights, and get the latest information.
Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation. 3(4):187-199. www.ncbi.nlm.nih.gov/pubmed/20965447
Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. J Clin Psychiatry. 75(12):1394-1401. www.ncbi.nlm.nih.gov/pubmed/25271871
Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 29(7):587-96. https://doi.org/10.1002/da.21969
Sackeim HA, et al. (2020). Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. Journal of Affective Disorders. 277:65-74. https://doi.org/10.1016/j.jad.2020.08.005